Alpha-internexin expression in gliomas: Relationship with histological type and 1p, 19q, 10p and 10q status

Journal of Clinical Pathology

Volumn 64, Issue 9, 2011, Pages 793-801

  Durand, Karine ^a   Guillaudeau, Angélique ^a   Pommepuy, Isabelle ^a   Mesturoux, Laura ^a   Chaunavel, Alain ^a   Gadeaud, Emilie ^a   Porcheron, Marion ^a   Moreau, Jean Jacques ^a   Labrousse, François ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERNEXIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; NESTIN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PROTEIN P53;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER PATIENT; CANCER SURGERY; CENTROMERE; CHEMORADIOTHERAPY; CHROMOSOME 10P; CHROMOSOME 10Q; CHROMOSOME 19Q; CHROMOSOME 1P; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENOMICS; GLIOBLASTOMA; GLIOMA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROSATELLITE MARKER; NEUROSURGERY; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; TELOMERE; TUMOR CELL; TUMOR GENE; TUMOR LOCALIZATION;

ADULT; AGED; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 19; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INTERMEDIATE FILAMENT PROTEINS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 80051891208     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.087668     Document Type: Article

References (45)

1. Dai C., Holland E.C. Astrocyte differentiation states and glioma formation. Cancer J 2003;9:72-81.
2. Louis D.N., Ohgaki H., Wiestler O.D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109. (Pubitemid 47103521)
3. Sanson M., Thillet J., Hoang-Xuan K. Molecular changes in gliomas. Curr Opin Oncol 2004;16:607-613 (Pubitemid 39482982)
4. Griffin C.A., Burger P., Morsberger L., et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006;65:988-994 (Pubitemid 44521799)
5. Jenkins R.B., Blair H., Ballman K.V., et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66:9852-9861 (Pubitemid 44672036)
6. Durand K.S., Guillaudeau A., Weinbreck N., et al. 1p19q LOH patterns and expression of p53 and Olig2 in gliomas: Relation with histological types and prognosis. Mod Pathol 2010;23:619-628
7. Aldape K., Burger P.C., Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 2007;131:242-251
8. Giannini C., Burger P.C., Berkey B.A., et al. Anaplastic oligodendroglial tumors: Refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 2008;18:360-369 (Pubitemid 351782844)
9. Eoli M., Bissola L., Bruzzone M.G., et al. Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer 2006;119:84-90.
10. Yakut T., Gutenberg A., Bekar A., et al. Correlation of chromosomal imbalances by comparative genomic hybridization and expression of EGFR, PTEN, p53, and MIB-1 in diffuse gliomas. Oncol Rep 2007;17:1037-1043
11. Arslantas A., Artan S., Oner U., et al. Genomic alterations in low-Grade, anaplastic astrocytomas and glioblastomas. Pathol Oncol Res 2007;13:39-46. (Pubitemid 46883545)
12. Hata N., Yoshimoto K., Yokoyama N., et al. Allelic losses of chromosome 10 in glioma tissues detected by quantitative single-strand conformation polymorphism analysis. Clin Chem 2006;52:370-378
13. Ichimura K., Schmidt E.E., Miyakawa A., et al. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer 1998;22:9-15. (Pubitemid 28217801)
14. Fujisawa H., Reis R.M., Nakamura M., et al. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 2000;80:65-72. (Pubitemid 30067381)
15. Maier D., Comparone D., Taylor E., et al. New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26. Oncogene 1997;15:997-1000. (Pubitemid 27399561)
16. Ohgaki H., Dessen P., Jourde B., et al. Genetic pathways to glioblastoma: A population-based study. Cancer Res 2004;64:6892-6899 (Pubitemid 39330996)
17. Hoang-Xuan K., He J., Huguet S., et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 2001;57:1278-1281 (Pubitemid 32947388)
18. Hoang-Xuan K., Idbaih A., Mokhtari K., et al. [Towards a molecular classification of gliomas]. Bull Cancer 2005;92:310-316
19. Lavon I., Zrihan D., Zelikovitch B., et al. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Clin Cancer Res 2007;13:1429-1437 (Pubitemid 46450432)
20. Ueki K., Nishikawa R., Nakazato Y., et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 2002;8:196-201. (Pubitemid 34101478)
21. Chan S.O., Chiu F.C. Cloning and developmental expression of human 66 kd neurofilament protein. Brain Res Mol Brain Res 1995;29:177-184
22. Foley J., Witte D., Chiu F.C., et al. Expression of the neural intermediate filament proteins peripherin and neurofilament-66/alpha-internexin in neuroblastoma. Lab Invest 1994;71:193-199 (Pubitemid 24278171)
23. Kaya B., Mena H., Miettinen M., et al. Alpha-internexin expression in medulloblastomas and atypical teratoid-rhabdoid tumors. Clin Neuropathol 2003;22:215-221 (Pubitemid 37152778)
24. Ikota H., Kinjo S., Yokoo H., et al. Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol 2006;111:475-482
25. Shirahata M., Iwao-Koizumi K., Saito S., et al. Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis. Clin Cancer Res 2007;13:7341-7356
26. Ferrer-Luna R., Mata M., Nunez L., et al. Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression. J Neurooncol 2009;95:343-354
27. Ducray F., Idbaih A., De Reynies A., et al. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer 2008;7:41.
28. Ducray F., Criniere E., Idbaih A., et al. Alpha-internexin expression identifies 1p19q codeleted gliomas. Neurology 2009;72:156-161
29. Guillaudeau A., Durand K., Pommepuy I., et al. Determination of EGFR status in gliomas: Usefulness of immunohistochemistry and fluorescent in situ hybridization. Appl Immunohistochem Mol Morphol 2009;17:220-226
30. Kraus J.A., Lamszus K., Glesmann N., et al. Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol 2001;101:311-320 (Pubitemid 32372420)
31. Mukasa A., Ueki K., Ge X., et al. Selective expression of a subset of neuronal genes in oligodendroglioma with chromosome 1p loss. Brain Pathol 2004;14:34-42. (Pubitemid 38200587)
32. Mukasa A., Ueki K., Matsumoto S., et al. Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene 2002;21:3961-3968 (Pubitemid 34679237)
33. Gresner S.M., Rieske P., Wozniak K., et al. Gliomas: Association of histology and molecular genetic analysis of chromosomes 1p, 10q, and 19q. Acta Neurobiol Exp (Wars) 2007;67:103-112 (Pubitemid 47066463)
34. Kramar F., Zemanova Z., Michalova K., et al. Cytogenetic analyses in 81 patients with brain gliomas: Correlation with clinical outcome and morphological data. J Neurooncol 2007;84:201-211 (Pubitemid 47202130)
35. Boulay J.L., Miserez A.R., Zweifel C., et al. Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors. PLoS One 2007;2:e576.
36. Ichimura K., Vogazianou A.P., Liu L., et al. 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene 2008;27:2097-2108 (Pubitemid 351442746)
37. Reddy K.S. Assessment of 1p/19q deletions by fluorescence in situ hybridization in gliomas. Cancer Genet Cytogenet 2008;184:77-86. (Pubitemid 351915763)
38. Burger P.C. What is an oligodendroglioma? Brain Pathol 2002;12:257-259 (Pubitemid 34259927)
39. Daumas-Duport C., Varlet P., Tucker M.L., et al. Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: Patterns of growth, histological diagnosis, clinical and imaging correlationsA study of 153 cases. J Neurooncol 1997;34:37-59. (Pubitemid 27270251)
40. McCarthy B.J., Propp J.M., Davis F.G., et al. Time trends in oligodendroglial and astrocytic tumor incidence. Neuroepidemiology 2008;30:34-44. (Pubitemid 351311724)
41. Nunes M.C., Roy N.S., Keyoung H.M., et al. Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nat Med 2003;9:439-447 (Pubitemid 36460078)
42. Lu Q.R., Sun T., Zhu Z., et al. Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection. Cell 2002;109:75-86. (Pubitemid 34327518)
43. Liang Y., Diehn M., Watson N., et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 2005;102:5814-5819 (Pubitemid 40559642)
44. Idbaih A., Marie Y., Lucchesi C., et al. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer 2008;122:1778-1786 (Pubitemid 351413424)
45. Yadav A.K., Renfrow J.J., Scholtens D.M., et al. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas. JAMA 2009;302:276-289